A Phase II Trial of Reduced Intensity Allogenenic Stem Cell Transplantation With Fludarabine, Melphalan and low Dose Total Body Irradiation
Description: 

Reduced intensity conditioning during allogeneic hematopoietic stem cell transplant (HSCT) reduces transplant related mortality (TRM) by relying more on the graft-versus-malignancy effect rather than the conditioning regimen to eradicate disease. Reduced intensity conditioning regimens can provide a curative option for patients with hematologic malignancies who might otherwise not be candidates for myeloablative (intensive) transplantation because of age or poor performance status. Since the ability to perform transplant safely is the primary measure of efficacy for reduced intensity conditioning, TRM is the appropriate measure of efficacy of the conditioning regimen.

Study Number: 

I 177110

Phase: 
II
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01529827

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.